Orthofix Medical Inc. Appoints New Directors, Updates Executive Compensation

Ticker: OFIX · Form: 8-K · Filed: Apr 12, 2024 · CIK: 884624

Sentiment: neutral

Topics: board-changes, executive-compensation, governance

Related Tickers: OFIX

TL;DR

Orthofix adds two new board members and finalizes exec pay packages.

AI Summary

Orthofix Medical Inc. announced on April 11, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Kevin Lobo and Ms. Jennifer L. Plosser, to its Board, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Ms. Catherine R. Vail, and its Chief Financial Officer, Mr. Douglas W. Butler, detailing their compensation packages.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and generally do not indicate significant new risks.

Key Players & Entities

FAQ

Who are the newly elected directors to Orthofix Medical Inc.'s Board?

Dr. Kevin Lobo and Ms. Jennifer L. Plosser were elected as new directors to the Board of Directors of Orthofix Medical Inc.

When were the new directors elected?

The new directors, Dr. Kevin Lobo and Ms. Jennifer L. Plosser, were elected to the Board of Directors effective April 11, 2024.

What other key information is disclosed in this 8-K filing?

The filing also discloses the appointment of certain officers and details regarding compensatory arrangements for certain officers, including new employment agreements for the CEO and CFO.

What is the principal executive office address for Orthofix Medical Inc.?

The principal executive offices of Orthofix Medical Inc. are located at 3451 Plano Parkway, Lewisville, Texas 75056.

What is the filing date of this 8-K report?

This 8-K report was filed as of April 12, 2024, with the date of the earliest event reported being April 11, 2024.

Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-12 16:30:19

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Orthofix Medical Inc. Date: April 12, 2024 By: /s/ Kimberley Elting Interim Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing